Whole Genome Sequencing (WGS)

Whole Genome Sequencing (WGS) designates comprehensive determination of the complete DNA sequence of an organism's genome, capturing coding and non-coding regions, structural variants, copy number changes, and single nucleotide alterations in a single analysis. This high-resolution genomic approach provides an unbiased view of genetic information enabling identification of known and novel variants influencing disease risk, therapeutic response, pathogen evolution, or biological function.

The biopharmaceutical industry applies WGS across drug discovery, translational research, clinical development, and manufacturing quality assurance. In target identification, WGS supports discovery of disease-associated variants through genome-wide association studies and rare disease sequencing. In oncology, tumour WGS identifies driver mutations, mutational signatures, and structural rearrangements guiding precision medicine strategies. Infectious disease applications include pathogen genome sequencing for outbreak investigation, antimicrobial resistance tracking, and surveillance of emerging variants. In cell and gene therapy manufacturing, WGS supports characterisation of engineered cell lines and evaluation of potential off-target edits. Operational challenges include large data volumes requiring robust bioinformatics infrastructure. As sequencing costs decline, computational tools improve, and evidence expands linking genetic variation to clinical outcomes, WGS continues advancing precision medicine by enabling deeper understanding of disease mechanisms and improving patient selection.